+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Low Back Pain - Pipeline Review, H2 2019

  • ID: 4894139
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 140 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Adynxx Inc
  • Bol Pharma
  • Grunenthal GmbH
  • Intec Pharma Ltd
  • Navipharm Co Ltd
  • Pfizer Inc
  • MORE
Low Back Pain - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Low Back Pain - Pipeline Review, H2 2019, provides an overview of the Low Back Pain (Central Nervous System) pipeline landscape.

Low back pain can happen anywhere below the ribs and above the legs. Causes of low back pain include overuse, strain, or injury, aging, arthritis, illness and cancer involving the spine. Symptoms include tingling or burning sensation, a dull achy feeling, or sharp pain and weakness in legs or feet. Treatment includes pain medications such NSAIDs (non-steroidal anti-inflammatory drugs) or opioids and muscle relaxants.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Low Back Pain - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Low Back Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Low Back Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Low Back Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 14, 6, 4 and 1 respectively.

Low Back Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Low Back Pain (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Low Back Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Low Back Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Low Back Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Low Back Pain (Central Nervous System)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Low Back Pain (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Low Back Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Adynxx Inc
  • Bol Pharma
  • Grunenthal GmbH
  • Intec Pharma Ltd
  • Navipharm Co Ltd
  • Pfizer Inc
  • MORE
Introduction
Report Coverage
Low Back Pain - Overview
Low Back Pain - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Low Back Pain - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Low Back Pain - Companies Involved in Therapeutics Development
Ache Laboratorios Farmaceuticos SA
Adynxx Inc
Allodynic Therapeutics LLC
AnGes Inc
Axsome Therapeutics Inc
BioRestorative Therapies Inc
Bol Pharma
Camurus AB
Daewon Pharmaceutical Co Ltd
Frontier Biotechnologies Inc
Gador SA
Grunenthal GmbH
Hisamitsu Pharmaceutical Co Inc
Imbrium Therapeutics LP
Immune Pharmaceuticals Inc
Inspyr Therapeutics Inc
Intec Pharma Ltd
MD Biosciences GmbH
Mesoblast Ltd
Navipharm Co Ltd
Nektar Therapeutics
Pacira BioSciences Inc
Pfizer Inc
Qingdao Chia Tai Haier Pharmaceutical Co Ltd
Scilex Holding Co
Stayble Therapeutics AB
Sun Pharma Advanced Research Company Ltd
Therapix Biosciences Ltd
WEX Pharmaceuticals Inc
Low Back Pain - Drug Profiles
(aceclofenac + eperisone SR) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(acetaminophen + caffeine + diclofenac sodium + orphenadrine) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(clonidine + naltrexone) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(eperisone + pelubiprofen) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(pregabalin PR + etoricoxib) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AB-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AK-1830 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AMG-0101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AYX-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BOLDPo-04 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BRTX-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bupivacaine ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
buprenorphine PR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cebranopadol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cyclobenzaprine hydrochloride SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dronabinol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dronabinol + palmidrol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HP-3150 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IG-8801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMB-9011010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lidocaine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lidocaine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MD-22 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MPC-06ID - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
oxycodegol phosphate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize ADORA2A for Arthritis Pain, Inflammation and Low Back Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STA-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STA-363 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tanezumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tetrodotoxin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
zoledronate disodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Low Back Pain - Dormant Projects
Low Back Pain - Discontinued Products
Low Back Pain - Product Development Milestones
Featured News & Press Releases
Jul 25, 2019: Nektar Therapeutics recieves General Advice letter from the U.S. FDA for NKTR-181
Sep 18, 2018: Camurus announces positive topline phase 3 results for CAM2038 in opioid experienced patients with chronic low-back pain
Jun 14, 2018: New Data for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Low Back Pain in Adult Patients New to Opioid Therapy, Presented at College on Problems of Drug Dependence 80th Annual Scientific Meeting
Jun 13, 2018: Analgesic Solutions Presents Data from the Implementation of its Misuse, Abuse, and Diversion Drug Event Reporting System (MADDERS)
May 31, 2018: Nektar Therapeutics Announces Submission of a New Drug Application to the U.S. FDA for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Low Back Pain in Adult Patients New to Opioid Therapy
Mar 29, 2018: Mesoblast Phase 3 Cell Therapy Trial for Chronic Low Back Pain Completes Enrollment
Mar 20, 2018: Therapix Biosciences Announces FDA Clearance of Investigational New Drug (IND) for Phase IIa Clinical Trial of THX-110 in the Treatment of Chronic Low Back Pain
Feb 27, 2018: AnGes Announces First Patient Treated with NF-kappa B Decoy in Phase Ib Study to Treat Discogenic Low Back Pain
Sep 25, 2017: Mesoblast Provides Update on lead product candidate MPC-06-ID at Global Healthcare Conferences
Jun 13, 2017: Pfizer and Lilly Receive FDA Fast Track Designation for Tanezumab
Apr 25, 2017: AnGes Announces FDA Clearance of Investigational New Drug Application for NF-kappaB decoy oligo DNA to treat discogenic lower back pain
Mar 24, 2017: AnGes: Investigational New Drug (IND) Application Submitted to the FDA
Mar 20, 2017: NKTR-181 Meets Primary and Secondary Endpoints in Phase 3 SUMMIT-07 Study in Chronic Pain
Mar 15, 2017: Durable Three-Year Outcomes In Degenerative Disc Disease After a Single Injection of Mesoblast’s Cell Therapy
Jan 09, 2017: BioRestorative Therapies Submits IND Application to FDA to Treat Patients with Degenerative Disc Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Low Back Pain, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Low Back Pain - Pipeline by Ache Laboratorios Farmaceuticos SA, H2 2019
Low Back Pain - Pipeline by Adynxx Inc, H2 2019
Low Back Pain - Pipeline by Allodynic Therapeutics LLC, H2 2019
Low Back Pain - Pipeline by AnGes Inc, H2 2019
Low Back Pain - Pipeline by Axsome Therapeutics Inc, H2 2019
Low Back Pain - Pipeline by BioRestorative Therapies Inc, H2 2019
Low Back Pain - Pipeline by Bol Pharma, H2 2019
Low Back Pain - Pipeline by Camurus AB, H2 2019
Low Back Pain - Pipeline by Daewon Pharmaceutical Co Ltd, H2 2019
Low Back Pain - Pipeline by Frontier Biotechnologies Inc, H2 2019
Low Back Pain - Pipeline by Gador SA, H2 2019
Low Back Pain - Pipeline by Grunenthal GmbH, H2 2019
Low Back Pain - Pipeline by Hisamitsu Pharmaceutical Co Inc, H2 2019
Low Back Pain - Pipeline by Imbrium Therapeutics LP, H2 2019
Low Back Pain - Pipeline by Immune Pharmaceuticals Inc, H2 2019
Low Back Pain - Pipeline by Inspyr Therapeutics Inc, H2 2019
Low Back Pain - Pipeline by Intec Pharma Ltd, H2 2019
Low Back Pain - Pipeline by MD Biosciences GmbH, H2 2019
Low Back Pain - Pipeline by Mesoblast Ltd, H2 2019
Low Back Pain - Pipeline by Navipharm Co Ltd, H2 2019
Low Back Pain - Pipeline by Nektar Therapeutics, H2 2019
Low Back Pain - Pipeline by Pacira BioSciences Inc, H2 2019
Low Back Pain - Pipeline by Pfizer Inc, H2 2019
Low Back Pain - Pipeline by Qingdao Chia Tai Haier Pharmaceutical Co Ltd, H2 2019
Low Back Pain - Pipeline by Scilex Holding Co, H2 2019
Low Back Pain - Pipeline by Stayble Therapeutics AB, H2 2019
Low Back Pain - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2019
Low Back Pain - Pipeline by Therapix Biosciences Ltd, H2 2019
Low Back Pain - Pipeline by WEX Pharmaceuticals Inc, H2 2019
Low Back Pain - Dormant Projects, H2 2019
Low Back Pain - Dormant Projects, H2 2019 (Contd..1), H2 2019
Low Back Pain - Discontinued Products, H2 2019

List of Figures
Number of Products under Development for Low Back Pain, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Ache Laboratorios Farmaceuticos SA
  • Adynxx Inc
  • Allodynic Therapeutics LLC
  • AnGes Inc
  • Axsome Therapeutics Inc
  • BioRestorative Therapies Inc
  • Bol Pharma
  • Camurus AB
  • Daewon Pharmaceutical Co Ltd
  • Frontier Biotechnologies Inc
  • Gador SA
  • Grunenthal GmbH
  • Hisamitsu Pharmaceutical Co Inc
  • Imbrium Therapeutics LP
  • Immune Pharmaceuticals Inc
  • Inspyr Therapeutics Inc
  • Intec Pharma Ltd
  • MD Biosciences GmbH
  • Mesoblast Ltd
  • Navipharm Co Ltd
  • Nektar Therapeutics
  • Pacira BioSciences Inc
  • Pfizer Inc
  • Qingdao Chia Tai Haier Pharmaceutical Co Ltd
  • Scilex Holding Co
  • Stayble Therapeutics AB
  • Sun Pharma Advanced Research Company Ltd
  • Therapix Biosciences Ltd
  • WEX Pharmaceuticals Inc
Note: Product cover images may vary from those shown
Adroll
adroll